|
HANNA: Real-world outcomes from an observational study with nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck in Germany. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; MSD; Roche; Takeda |
Travel, Accommodations, Expenses - Celgene; Merck |
|
|
|
Stock and Other Ownership Interests - Lilly (I) |
Consulting or Advisory Role - Bristol-Myers Squibb; MSD |
|
Travel, Accommodations, Expenses - MSD |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bristol-Myers Squibb; Merck; MSD |
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; MSD |
Research Funding - Bristol-Myers Squibb |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck; MSD |
|
Jorge Riera-Knorrenschild |
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb |
Speakers' Bureau - Merck Serono |
Research Funding - Bristol-Myers Squibb (Inst) |
Expert Testimony - Clinigen Group |
Travel, Accommodations, Expenses - Clinigen Group |
|
|
Travel, Accommodations, Expenses - Novartis |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Bayer |
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Ipsen; Novartis |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Eisai; Ipsen; Novartis |
|
|
Employment - Bristol-Myers Squibb; Bristol-Myers Squibb GMbH and Co. KGaA |
|
|
Employment - Partner in the oncology practice at Raschplatz, Hannover |
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; EUSA Pharma; Merck; MSD; Novartis; Roche |
Research Funding - Amgen; Boehringer Ingelheim; Bristol-Myers Squibb; Ipsen; Lilly; Novartis; Sanofi |